Literature DB >> 31257207

Duration of anticoagulant treatment for unprovoked deep-vein thrombosis - is prolonged long enough?

Menno V Huisman1, Frederikus A Klok1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31257207      PMCID： PMC6601085          DOI： 10.3324/haematol.2019.218909

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  16 in total

1.  High percentage of non-diagnostic compression ultrasonography results and the diagnosis of ipsilateral recurrent proximal deep vein thrombosis.

Authors:  M Tan; S I Velthuis; R E Westerbeek; C J VAN Rooden; F J M VAN DER Meer; M V Huisman
Journal:  J Thromb Haemost       Date:  2010-04       Impact factor: 5.824

2.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Authors:  Harry R Büller; Hervé Décousus; Michael A Grosso; Michele Mercuri; Saskia Middeldorp; Martin H Prins; Gary E Raskob; Sebastian M Schellong; Lee Schwocho; Annelise Segers; Minggao Shi; Peter Verhamme; Phil Wells
Journal:  N Engl J Med       Date:  2013-08-31       Impact factor: 91.245

3.  Risk of fatal pulmonary embolism in patients with treated venous thromboembolism.

Authors:  J D Douketis; C Kearon; S Bates; E K Duku; J S Ginsberg
Journal:  JAMA       Date:  1998-02-11       Impact factor: 56.272

4.  Oral apixaban for the treatment of acute venous thromboembolism.

Authors:  Giancarlo Agnelli; Harry R Buller; Alexander Cohen; Madelyn Curto; Alexander S Gallus; Margot Johnson; Urszula Masiukiewicz; Raphael Pak; John Thompson; Gary E Raskob; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2013-07-01       Impact factor: 91.245

5.  Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.

Authors:  G Agnelli; P Prandoni; M G Santamaria; P Bagatella; A Iorio; M Bazzan; M Moia; G Guazzaloca; A Bertoldi; C Tomasi; G Scannapieco; W Ageno
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

6.  A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.

Authors:  C Kearon; M Gent; J Hirsh; J Weitz; M J Kovacs; D R Anderson; A G Turpie; D Green; J S Ginsberg; P Wells; B MacKinnon; J A Julian
Journal:  N Engl J Med       Date:  1999-03-25       Impact factor: 91.245

7.  Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review.

Authors:  Sake J van der Wall; Liselotte M van der Pol; Yvonne M Ende-Verhaar; Suzanne C Cannegieter; Sam Schulman; Paolo Prandoni; Marc Rodger; Menno V Huisman; Frederikus A Klok
Journal:  Eur Respir Rev       Date:  2018-11-28

8.  Extended oral anticoagulant therapy after a first episode of pulmonary embolism.

Authors:  Giancarlo Agnelli; Paolo Prandoni; Cecilia Becattini; Mauro Silingardi; Maria Rita Taliani; Maddalena Miccio; Davide Imberti; Renzo Poggio; Walter Ageno; Enrico Pogliani; Fernando Porro; Pietro Zonzin
Journal:  Ann Intern Med       Date:  2003-07-01       Impact factor: 25.391

9.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

10.  The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism.

Authors:  James D Douketis; Chu Shu Gu; Sam Schulman; Angelo Ghirarduzzi; Vittorio Pengo; Paolo Prandoni
Journal:  Ann Intern Med       Date:  2007-12-04       Impact factor: 25.391
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.